First Manhattan’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

First Manhattan’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-37,683	Closed	-$26K	–	1600
2020 Q4	$26K	Sell	37,683 -12,939	-26%	-$27.6K	﹤0.01%	1013
2020 Q3	$113K	Sell	50,622 -1,000	-2%	-$2.86K	﹤0.01%	758
2020 Q2	$184K	Sell	51,622 -3,000	-5%	-$10.8K	﹤0.01%	668
2020 Q1	$207K	Sell	54,622 -5,000	-8%	-$16.5K	﹤0.01%	610
2019 Q4	$179K	Buy	+59,622	New	+$155K	﹤0.01%	710

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

First Manhattan's BMY.RT Position: Q1 2021 in Review

First Manhattan sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 37,683 shares — an estimated $26K sold.

First Manhattan first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $207K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

First Manhattan reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
First Manhattan sold 37,683 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $26K.
First Manhattan first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
First Manhattan's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $207K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on First Manhattan's 13F filing for Q1 2021, filed 14 May 2021.